Summary & Overview
HCPCS Q5115: Injection, rituximab-abbs (Truxima), 10 mg
HCPCS Level II code Q5115 denotes the biosimilar rituximab product Truxima, billed per 10 mg unit for parenteral administration. This biologic agent is used across multiple specialty settings for immune-mediated diseases and oncology indications where rituximab is indicated. Nationally, clear coding for biosimilars like Q5115 matters for accurate drug identification, payment processing, inventory tracking, and biosimilar adoption monitoring.
Key payers covered in this overview include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will find a concise explanation of the clinical and billing context for Q5115, typical sites of service, and which stakeholders commonly encounter this code. The publication also outlines what to expect in benchmarking and policy coverage discussions: payment benchmarks for biosimilar rituximab, coding guidance considerations, and payer coverage patterns.
This summary prepares clinicians, coding professionals, and policy analysts to understand where Q5115 fits in drug billing workflows, what services it represents, and which major payers are relevant for coverage and reimbursement conversations. Data not available in the input is noted where applicable.
Billing Code Overview
HCPCS Level II code Q5115 represents injection, rituximab-abbs, biosimilar (Truxima), 10 mg. The code describes a biologic biosimilar product of rituximab supplied for parenteral administration.
-
Service type: Drug administration (intravenous or subcutaneous biologic infusion/injection)
-
Typical site of service: Ambulatory infusion clinic, hospital outpatient department, physician office, or other outpatient infusion setting
Data not available in the input for associated taxonomies, ICD-10 diagnoses, and related codes.
Clinical & Coding Specifications
Clinical Context
A 62-year-old female with newly diagnosed follicular non-Hodgkin lymphoma presents to the outpatient oncology infusion center for initiation of chemoimmunotherapy. The treatment plan includes intravenous rituximab biosimilar (Truxima) administered per weight-based dosing. The infusion visit is scheduled after pre-infusion nursing assessment, vitals, and review of prior infusion reactions and current medications. Antiemetic and premedication orders (acetaminophen, antihistamine, and corticosteroid) are administered as required. The nurse prepares the appropriate number of Q5115 10 mg vials based on the calculated dose, labels the infusion bag, and starts the infusion under direct supervision of the oncology physician or advanced practice provider. Vitals are monitored at baseline and periodically during infusion; any infusion-related reactions are managed per protocol (stop infusion, give rescue medications, document). After completion, the patient is observed for a short recovery period and discharged with instructions for follow-up and next cycle scheduling. Typical sites of service are hospital outpatient infusion centers and freestanding oncology infusion clinics. Common payer interactions involve prior authorization for biologics through Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, BUCA, and Medicare.
Coding Specifications
| Modifier | Description | When to Use |
|---|---|---|
JW | Drug or biological quantity discarded/not administered |